Literature DB >> 33479611

Antiproliferative activities of tricyclic amides derived from β-caryophyllene via the Ritter reaction against MDA-MB-231 breast cancer cells.

XiXi Xu1, Ariane Roseblade1, Tristan Rawling1, Alison T Ung1.   

Abstract

A library of novel tricyclic amides has been synthesised via the Ritter reaction from β-caryophyllene 1 and its monoepoxy derivative 4. The compounds were assessed for antiproliferative activities against the aggressive MDA-MB-231 breast cancer cell line. Of the synthesised compounds, eight were active. 3c and 6b were the most potent and inhibited proliferation with IC50 of 9.7 and 8.2 μM, respectively. Mechanistic studies revealed differences in their antiproliferative actions. 6b inhibited cell cycle progression and induced predominantly apoptotic cell death. In contrast, 3c did not affect cell cycle kinetics and favoured necrotic over apoptotic pathways. Screening against mammalian cells (VERO cells) indicates that 3c and 6b were more active towards MDA-MB-231 cells than noncancerous cells. Facile synthesis and biological results suggest that these caryophyllene derived amides are viable lead compounds for further development. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2019        PMID: 33479611      PMCID: PMC7439098          DOI: 10.1039/c9md00237e

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  11 in total

Review 1.  Natural Products as Sources of New Drugs from 1981 to 2014.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2016-02-07       Impact factor: 4.050

2.  Subtype and pathway specific responses to anticancer compounds in breast cancer.

Authors:  Laura M Heiser; Anguraj Sadanandam; Wen-Lin Kuo; Stephen C Benz; Theodore C Goldstein; Sam Ng; William J Gibb; Nicholas J Wang; Safiyyah Ziyad; Frances Tong; Nora Bayani; Zhi Hu; Jessica I Billig; Andrea Dueregger; Sophia Lewis; Lakshmi Jakkula; James E Korkola; Steffen Durinck; François Pepin; Yinghui Guan; Elizabeth Purdom; Pierre Neuvial; Henrik Bengtsson; Kenneth W Wood; Peter G Smith; Lyubomir T Vassilev; Bryan T Hennessy; Joel Greshock; Kurtis E Bachman; Mary Ann Hardwicke; John W Park; Laurence J Marton; Denise M Wolf; Eric A Collisson; Richard M Neve; Gordon B Mills; Terence P Speed; Heidi S Feiler; Richard F Wooster; David Haussler; Joshua M Stuart; Joe W Gray; Paul T Spellman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-14       Impact factor: 11.205

Review 3.  Impact of natural products on developing new anti-cancer agents.

Authors:  Gordon M Cragg; Paul G Grothaus; David J Newman
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

4.  Mechanisms of multidrug resistance in cancer.

Authors:  Jean-Pierre Gillet; Michael M Gottesman
Journal:  Methods Mol Biol       Date:  2010

5.  Past, present, and future challenges in breast cancer treatment.

Authors:  George W Sledge; Eleftherios P Mamounas; Gabriel N Hortobagyi; Harold J Burstein; Pamela J Goodwin; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

6.  Copper-catalyzed alkene arylation with diaryliodonium salts.

Authors:  Robert J Phipps; Lindsay McMurray; Stefanie Ritter; Hung A Duong; Matthew J Gaunt
Journal:  J Am Chem Soc       Date:  2012-06-19       Impact factor: 15.419

Review 7.  Multiple drug resistance mechanisms in cancer.

Authors:  Bruce C Baguley
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

8.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.

Authors:  John Stagg; Bertrand Allard
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

9.  Potentiating effect of beta-caryophyllene on anticancer activity of alpha-humulene, isocaryophyllene and paclitaxel.

Authors:  Jean Legault; André Pichette
Journal:  J Pharm Pharmacol       Date:  2007-12       Impact factor: 3.765

10.  Antiproliferative activities of alkaloid-like compounds.

Authors:  XiXi Xu; Tristan Rawling; Ariane Roseblade; Roger Bishop; Alison T Ung
Journal:  Medchemcomm       Date:  2017-10-25       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.